? Core C (Primate Studies) This HIVRAD proposal is based on our data that the dimeric IgA1 (dIgA1) form of a neutralizing monoclonal antibody (nmAb) given intrarectally (i.r.) protected most rhesus macaques (RMs) against i.r. clade C simian- human immunodeficiency virus (SHIV-C) challenge; dIgA2 yielded minimal protection, although both dIgA2 and dIgA1 neutralized SHIV-C equally well in vitro. In a 2nd study, intravenous (i.v.) administration of the nmAb as IgG1 and i.r. as dIgA2 gave 100% protection, whereas the same nmAbs given alone gave no or low protection. A better understanding of this synergy is the aim of Project 1. Project 2 will test systemically administered monoclonal IgGs ? both neutralizing and non-neutralizing and inducible by current immunogens ? and/or mucosally delivered dIgAs for efficacy against SHIV-C alone or in combination. Project 3 will test a novel lymph node (LN)-targeting technology to induce immune responses at the mucosal level, the portal of virus entry. The overall objective of Core C is to provide experimental RMs and support services (animal care, veterinary care, and surgical procedures) to achieve the goals of all three Projects. Core C will identify suitable RMs from the specific pathogen-free (SPF) colonies at the Southwest National Primate Research Center (SNPRC) and will perform MHC class I (Mamu A*01, B*08, B*17) genotyping to provide suitable RMs. Core C will perform i.r. titrations of a new tier 2 SHIV-C stock (SHIV-1157ipd3N4) to determine the dose to challenge RMs by single high-dose exposure (Project 2) and by repeated low-dose exposures (Project 3). Core C will carry out passive administration of mAbs by the appropriate route to RMs for Project 1 and 2; vaccinate (prime and boost) the RMs with novel LN-targeting immunogens for Project 3 and also perform the following tasks: Project 1: exposure of fluorescently labeled virus to mucosa and collection of the biopsies and/or mucosal fluids for ex vivo analysis; Project 2: single high-dose i.r. SHIV-C challenge, followed by periodic collection of required specimens (blood and/or mucosal specimens) for assessment of plasma viremia and antibody levels; Project 3: periodic collection of specimens (blood and/or mucosal specimens) for assessment of vaccine immunogenicity, i.r. repeated low-dose virus challenges, and periodic collection of post-challenge specimens (blood and/or mucosal specimens) for assessment of vaccine efficacy; Core D: coordinate and manage the transport of RMs between SNPRC and the Research Imaging Institute (Core D). Using radiolabeled mAbs and virus, Core D will perform PET scans to follow virus- antibody interactions (Project 1); trafficking of radiolabeled immunogens to mucosal LNs will be investigated for Project 3. RM specimens will be provided to Projects and/or Core B for analysis. Core C will also perform necropsies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI048240-14
Application #
9509345
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
14
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Texas Biomedical Research Institute
Department
Type
DUNS #
007936834
City
San Antonio
State
TX
Country
United States
Zip Code
78245
Tokatlian, Talar; Kulp, Daniel W; Mutafyan, Andrew A et al. (2018) Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. Sci Rep 8:16527
Ruprecht, Ruth M; Lakhashe, Samir K (2017) Antibody-mediated immune exclusion of HIV. Curr Opin HIV AIDS 12:222-228
Ruprecht, Ruth M (2017) Anti-HIV Passive Immunization: New Weapons in the Arsenal. Trends Microbiol 25:954-956
Schneider, Jeffrey R; Carias, Ann M; Bastian, Arangaserry R et al. (2017) Long-term direct visualization of passively transferred fluorophore-conjugated antibodies. J Immunol Methods 450:66-72
Kulkarni, Viraj; Ruprecht, Ruth M (2017) Mucosal IgA Responses: Damaged in Established HIV Infection-Yet, Effective Weapon against HIV Transmission. Front Immunol 8:1581
Sholukh, Anton M; Watkins, Jennifer D; Vyas, Hemant K et al. (2015) Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 33:2086-95
Lakhashe, Samir K; Byrareddy, Siddappa N; Zhou, Mingkui et al. (2014) Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine 32:6527-36
Zhou, Mingkui; Ruprecht, Ruth M (2014) Are anti-HIV IgAs good guys or bad guys? Retrovirology 11:109
Sholukh, Anton M; Byrareddy, Siddappa N; Shanmuganathan, Vivekanandan et al. (2014) Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology 11:8
Bachler, Barbara C; Humbert, Michael; Lakhashe, Samir K et al. (2013) Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia. Retrovirology 10:63

Showing the most recent 10 out of 77 publications